- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01456208
Genetic Mechanisms in Human Hypertension
Vascular Disease and Hbp: Pai-1, Insulin and Genes (Crc): Hypertension Phenotype
Thank you for your interest in the investigators Genetics and Blood Pressure Research Study. The National Institutes of Health are sponsoring us to investigate why patients develop high blood pressure, atherosclerosis (hardening of the arteries), and heart disease. There are two parts of the investigators research program. The first part is a screening visit. At this visit you will be given a brief physical exam and will be asked questions concerning your medical history. During the same visit you will have your blood drawn for routine screening and to prepare DNA for genetic testing. You will also be asked to collect a urine sample for routine screening.
If the doctor finds that you are a healthy candidate you will be invited to participate in the second part of the study. During Phase II, the investigators will perform physiological tests after you are placed on a low salt diet and again after you are placed on a high salt diet. If you are on blood pressure medication, it may be necessary to discontinue taking your present medication for up to three months before beginning the study. Patients discontinuing their current blood pressure medication may be placed on a different blood pressure medication during this washout period if necessary to maintain blood pressure at pre-study levels. The investigators will take you off all medications at about two weeks prior to your scheduled in-patient study (overnight visits).
Once your blood pressure medications are discontinued, you will be closely monitored to make sure you do not encounter any difficulty. If you do not own a home blood pressure monitor, the investigators will provide one for you to use during the study so that you can keep a daily record of your blood pressure readings. The investigators will ask you to call us every three days to report your blood pressure readings. Less than 20% of patients have any significant increase in their blood pressure during this short time off of therapy. After you have stopped taking your medication, dieticians at the hospital will make you low salt meals to eat at home for seven days. On the seventh day of the low salt diet, you will be asked to begin a 24-hour urine collection that you will bring with you when you are admitted to the hospital that evening. That morning, you will be required to come to the Clinical Research Center for a one-hour test to check if your body is in the correct salt balance. You will return that evening to the inpatient Clinical Research Center where you will be admitted for your study that will occur the next morning. On the morning of your low salt study, you will have naturally occurring hormones administered and blood samples drawn from an intravenous needle. The investigators will also take ultrasound pictures of your heart to see how salt and hormones affect the way the heart functions. These tests will last approximately five hours and you will be discharged around 2:00 PM. For the next five days, you will be placed on a high salt diet. During these five days, you will eat all your own food, but the investigators will give you some supplements to eat with your meals. After five days on your high salt diet, on the morning of your second admission to the hospital, you will be asked to begin a final 24-hour urine collection. That morning, you will again be required to come to the Clinical Research Center for a one-hour test to check if your body is in the correct salt balance. You will return that evening to the inpatient Clinical Research Center where you will be admitted for your final study that will occur the next morning. The same study that was done for the low salt study will be repeated for the high salt study. You will be discharged around 2:00 p.m. This study will determine if you are salt-sensitive. In addition, the investigators hope to learn more about the hormones that regulate your blood pressure and the genes responsible for regulating those hormones.
You will be placed back on your initial blood pressure medication (if you are on any) and returned to your regular physician for care. The investigators will provide clinically relevant information to you and your physician.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Age 18-65
- A history of hypertension diagnosis and/or use of hypertension medications
- BMI < or equal to 40
Description
Inclusion Criteria:
- Age 18-65
- A history of hypertension diagnosis and/or use of hypertension medications
- BMI < or equal to 40
Exclusion Criteria:
- Any other major illnesses
- Subjects with current excessive alcohol use (greater than 12 oz/ETOH/week) or recreational drug use
- BMI > 40
- Taking birth control or contraceptive hormone shots or implants
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Independent Genetic Variants in the R-A-A System Predict Characteristics of Specific Intermediate Phenotypes of Hypertension (non-modulation and low renin).
Time Frame: 13 years
|
|
13 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gordon H Williams, MD, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Serine Proteinase Inhibitors
- Sympathomimetics
- Vasoconstrictor Agents
- Norepinephrine
- Angiotensin II
- Giapreza
- Angiotensinogen
Other Study ID Numbers
- 1999P002189
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Para-aminohippuric Acid
-
University of Colorado, DenverActive, not recruitingObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Complications | Type 2 Diabetes Mellitus | Pediatric Obesity | Diabetic Kidney Disease | Diabetic Nephropathies | Weight Loss | Bariatric Surgery Candidate | Adolescent Obesity | NephropathyUnited States
-
University of Colorado, DenverActive, not recruitingObesity | Type 2 Diabetes Mellitus | Adolescent Obesity | NephropathyUnited States
-
University of Colorado, DenverCompletedDiabetes Mellitus, Type 1 | Diabetic Nephropathies | Type 1 Diabetes Mellitus | Diabetes Mellitus Complication | Nephropathy | Autoimmune Diabetes | Juvenile DiabetesUnited States
-
Brigham and Women's HospitalWithdrawn
-
Florida International UniversityUniversity of Southern California; Universidad Peruana Cayetano HerediaRecruitingHIV Infections | Sexually Transmitted Diseases | Hiv | Sexual Behavior | Risk Reduction | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
University of Colorado, DenverJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus | Diabetes | Diabetes Complications | Type1diabetes | Type 1 Diabetes | Diabetic Kidney Disease | Diabetic Nephropathies | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes, Autoimmune | Juvenile DiabetesUnited States
-
University of Colorado, DenverCompletedPolycystic Kidney, Autosomal Dominant | Polycystic Kidney Disease, AdultUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingType 2 Diabetes Mellitus | Diabetic Kidney Disease | Adolescent Obesity | Puberty | Pre Diabetes | Kidney HypoxiaUnited States
-
University of Colorado, DenverEnrolling by invitationObesity | Diabetic Kidney Disease | Diabetic Nephropathies | Type 2 Diabetes | Adolescent Obesity | Nephropathy | Diabetes Type 2United States
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Type 1 Diabetes | Diabetic Kidney Disease | Endothelial Dysfunction | Insulin SensitivityUnited States